---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116285"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:32:14.679352+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics receives Nasdaq bid price deficiency notice; faces dual listing compliance issues

## Summary
- Common stock failed minimum $1.00 closing bid for 30 consecutive days through Nov 6, 2023.
- Company has 180 calendar days, until May 6, 2024, to regain bid price compliance.
- Also under stockholders' equity deficiency; Nasdaq panel granted exception until Jan 22, 2024 to demonstrate compliance.
- Company may consider a reverse stock split to regain compliance with bid price rule.

## SEC filing metadata
- accession: 0001104659-23-116285
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465923116285/0001104659-23-116285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465923116285/tm2330305d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116285
- JSON: https://secwatch.observer/filing/0001104659-23-116285.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116285.txt

## Key facts
- Listing & Compliance Notices
  Transcode Therapeutics, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5815(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5815(a)(2)
  source text: October 26, 2023, the Company received written notice from Nasdaq (the “October Notification Letter”) that the Panel had granted the Company an exception from compliance with the Stockholders Equity Requirement and extension of continued listing until January 22, 2024, subject to the following: 1. On or before November 14, 2023, the Company shall provide a detailed update to the Panel regarding its meeting the Stockholders’ Equity Requirement; and 2. On or before January 22, 2024, the Company shall provide an update to the Panel on how it demonstrates long-term compliance with the Stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465923116285/0001104659-23-116285-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.